Business
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Resul...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Conference call and webcast to take place on\n \n Thursday, May 5, 2022\n \n , at\n \n 5:00 p.m. ET\n \n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n \n ,\n \n \n April 28, 2022\n \n \n /CNW/ --Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on\n \n Thursday, May 5, 2022\n \n , at\n \n 5:00 p.m. ET\n \n to discuss a corporate update and financial results for the first quarter of 2022.\n \n \n \n \n \n \n \n \n \n \n \n Conference Call & Webcast\n \n \n \n \n \n Date:\n \n Thursday, May 5, 2022\n \n \n Time:\n \n 5:00 p.m. ET\n \n \n Dial In – North American Toll-Free:\n \n (888) 664-6383\n \n \n Dial In – International:\n \n (416) 764-8650\n \n \n Conference ID\n \n (if needed)\n \n :\n \n 6952-6976\n \n \n Webcast:\n \n please\n \n click here\n \n \n \n A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking\n \n here\n \n , and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (\n \n North America\n \n ) or (416) 764-8677 (International) and using replay code: 526-976#.\n \n \n \n About Oncolytics Biotech Inc.\n \n \n \n Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning \"cold\" tumors \"hot\" -- through innate and adaptive immune responses to treat a variety of cancers.\n \n \n Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkp...